



# DECEMBER SEMINAR NOTICE

Presented by

Yale School of Medicine's, Department of Therapeutic Radiology

# "Clinical Updates in Radiation Oncology: Gynecologic Malignancies" Shari Damast, MD Associate Professor of Therapeutic Radiology Director, Gynecologic Radiotherapy Program

Date: Thursday, December 17, 2020, 9:00AM Location: Zoom Meeting

**Yale School of Medicine** 

Course Director/Host: Henry S. Park, MD, MPH

There is no corporate support for this activity

This course will fulfill the ligarity requirement set forth by the State of C.

This course will fulfill the licensure requirement set forth by the State of Connecticut

## ACCREDITATION

The Yale School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

### TARGET AUDIENCE

Attending Physicians; Housestaff/Fellows; Medical Students; Nurses; PA's; Other

# NEEDS ASSESSMENT

A decline in brachytherapy (BT) use for cervical cancer has negatively affected cure rates in the United States and abroad and a need to educate physicians on brachytherapy practice and technique has been identified (Damast S *et al* Brachytherapy Nov 2020 PMID: 33221261)

Recent clinical trials have been seemingly contradictory on the role of radiotherapy in endometrial cancer and context and commentary are needed to help draw a consistent narrative path supporting the use of RT in uterine cancer (Chino J *et al* IJROBP Nov 2020 PMID: 33069345).

Physicians will benefit from awareness of biomarkers under study and exciting treatments on the horizon such as immunotherapy which have shown real promise for the future in both cancers of the uterine corpus and cervix (Lin LL *et al* IJGC Apr 2020 PMID: 32193219).

### **LEARNING OBJECTIVES**

At the conclusion of this activity, participants will be able to:

- Appreciate advances in image guided brachytherapy for cervical cancer.
- 2. Understand modern approaches of integrating chemotherapy with radiotherapy for endometrial cancer.
- 3. Learn about recent and ongoing clinical trials investigating immunotherapy and molecular-driven treatments for gynecologic cancers.

# **DESIGNATION STATEMENT**

The Yale School of Medicine designates this live activity for 1 AMA PRA Category 1 Credit(s)<sup>TM</sup>. Physicians should only claim the credit commensurate with the extent of their participation in the activity.

### FACULTY DISCLOSURES

Shari Damast, MD – None; Henry S. Park, MD, MPH – RadOncQuestions, LLC, Honorarium, Editor

It is the policy of Yale School of Medicine, Continuing Medical Education, to ensure balance, independence, objectivity and scientific rigor in all its educational programs. All faculty participating as speakers in these programs are required to disclose any relevant financial relationship(s) they (or spouse or partner) have with a commercial interest that benefits the individual in any financial amount that has occurred within the past 12 months; and the opportunity to affect the content of CME about the products or services of the commercial interests. The Center for Continuing Medical Education will ensure that any conflicts of interest are resolved before the educational activity occurs.